Q1: A decent start to the year
13/05/22 -"Lundbeck has started the year on a decent note. While sales declined in constant currency terms, this had largely been expected due to Northera’s patent expiry. Encouragingly, substantial growth ..."
Pages
56
Language
English
Published on
13/05/22
You may also be interested by these reports :
14/07/25
We have refined our estimates for the forecasting period by removing the €100m financing measure and the associated issuance of approximately 14 ...
14/07/25
BioNTech’s acquisition of CureVac was a strategic move. This decision resolves potential costly issues, including the patent dispute with CureVac, ...
09/07/25
After integrating the latest figures, we have refined our profitability expectations for the coming years. Given the robust business model, we ...
01/07/25
Back in late-2023, when Sanofi abandoned its 2025 profitability targets to step up its internal R&D efforts, the management had highlighted 12 ...